| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1081: Zanubrutinib for treating relapsed or refractory mantle cell lymphoma |
|
Medicine details |
|
| Medicine name | zanubrutinib (Brukinsa®) |
| Formulation | 80 mg hard capsule |
| Reference number | 5408 |
| Indication | As monotherapy for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy |
| Company | BeiGene |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| NICE guidance | TA1081: Zanubrutinib for treating relapsed or refractory mantle cell lymphoma |